Andere talen Apellis Pharmaceuticals, Inc.

Aandelen

APLS

US03753U1060

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
49,86 ^USD	+4,03%		+4,90%	-16,71%

26/04	Apellis Pharmaceuticals zegt dat EMA de aanvraag voor Pegcetacoplan naar de laatste fase van de initiële beoordeling verplaatst	MT
26/04	Apellis kondigt aan dat het Europees Geneesmiddelenbureau de beoordeling van de MAA voor Pegcetacoplan heeft teruggezet naar de eerste beoordeling	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment	26/04
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)	26/04
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency	26/04
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results	23/04
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	09/04
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	01/04
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	21/03
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	20/03
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	14/03
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor	11/03
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	11/03
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	07/03
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing	05/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	27/02
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Apellis Pharmaceuticals, Inc.

Aandelen

APLS

US03753U1060

Andere talen

Filters